

Australian Technical Advisory Group on Immunisation (ATAGI) recommended COVID-19 vaccines and doses

The table below summarises the Australian Technical Advisory Group on Immunisation (ATAGI) recommendations relating to COVID-19 vaccines and required doses.

GROUP	VACCINES	PRIMARY COURSE	BOOSTER	WINTER DOSE
GENERAL POPULATION				
5 years	Pfizer (COMIRNATY) (For Ages 5 to <12)	FIRST DOSE → SECOND DOSE	Not approved or recommended.	Not approved or recommended.
6 – 11 years	Pfizer (COMIRNATY) (For Ages 5 to <12) Moderna (SPIKEVAX) [^]	FIRST DOSE → SECOND DOSE	Not approved or recommended.	Not approved or recommended.
12 – 15 years	Pfizer (COMIRNATY) Moderna (SPIKEVAX)	FIRST DOSE → SECOND DOSE	Pfizer (COMIRNATY): approved but not recommended. Moderna (SPIKEVAX): not approved or recommended	Not approved or recommended.
16 – 17 years	Pfizer (COMIRNATY)* Moderna (SPIKEVAX)	FIRST DOSE → SECOND DOSE	BOOSTER ONLY PFIZER APPROVED 3 months after Primary Course	Not approved or recommended.
18 – 64 years	Pfizer (COMIRNATY) Moderna (SPIKEVAX) Novavax (NUVAXOVID)** AstraZeneca (VAXZEVRIA)	FIRST DOSE → SECOND DOSE	BOOSTER 3 months after Primary Course	Not approved or recommended.
65+ years	Pfizer (COMIRNATY) Moderna (SPIKEVAX) Novavax (NUVAXOVID)** AstraZeneca (VAXZEVRIA)	FIRST DOSE → SECOND DOSE	BOOSTER 3 months after Primary Course	WINTER DOSE From 4 months after Booster
SPECIAL POPULATION				
5 years Severely immunocompromised	Pfizer (COMIRNATY) (For Ages 5 to <12)	FIRST DOSE → SECOND DOSE → THIRD DOSE Third dose 2 months after second dose	Not approved or recommended.	Not approved or recommended.
6 – 11 years Severely immunocompromised	Pfizer (COMIRNATY) (For Ages 5 to <12) Moderna (SPIKEVAX) [^]	FIRST DOSE → SECOND DOSE → THIRD DOSE Third dose 2 months after second dose	Not approved or recommended.	Not approved or recommended.
12 – 15 years Severely immunocompromised	Pfizer (COMIRNATY) Moderna (SPIKEVAX)	FIRST DOSE → SECOND DOSE → THIRD DOSE Third dose 2 months after second dose	Pfizer (COMIRNATY): approved but not recommended. Moderna (SPIKEVAX): not approved or recommended	Not approved or recommended.
16-17 years Severely immunocompromised	Pfizer (COMIRNATY)* Moderna (SPIKEVAX)	FIRST DOSE → SECOND DOSE → THIRD DOSE Third dose 2 months after second dose	BOOSTER ONLY PFIZER APPROVED 3 months after Primary Course	WINTER DOSE ONLY PFIZER APPROVED From 4 months after Booster
18+ years Severely immunocompromised	Pfizer (COMIRNATY) Moderna (SPIKEVAX) Novavax (NUVAXOVID)** AstraZeneca (VAXZEVRIA)	FIRST DOSE → SECOND DOSE → THIRD DOSE Third dose 2 months after second dose	BOOSTER 3 months after Primary Course	WINTER DOSE From 4 months after Booster
Pregnant, breastfeeding or planning pregnancy	Pfizer (COMIRNATY)* Moderna (SPIKEVAX) Novavax (NUVAXOVID)** (18+) AstraZeneca (VAXZEVRIA) (18+)	FIRST DOSE → SECOND DOSE	BOOSTER 3 months after Primary Course	Not approved or recommended.
Residents of aged care or disability care facilities	Pfizer (COMIRNATY)* Moderna (SPIKEVAX) Novavax (NUVAXOVID)** (18+) AstraZeneca (VAXZEVRIA) (18+)	FIRST DOSE → SECOND DOSE	BOOSTER 3 months after Primary Course	WINTER DOSE From 4 months after Booster
Aboriginal and Torres Strait Islander people aged 50+ years	Pfizer (COMIRNATY) Moderna (SPIKEVAX) Novavax (NUVAXOVID)** AstraZeneca (VAXZEVRIA)	FIRST DOSE → SECOND DOSE	BOOSTER 3 months after Primary Course	WINTER DOSE From 4 months after Booster

Notes

[^] There is no separate paediatric formulation of the Moderna vaccine – children aged 6 to 11 years receive half the adult dose (50µg in 0.25 mL). ATAGI recommends that providers are vigilant about the potential for dosing errors, including overdosing, with the Moderna vaccine in children.

* For people aged 16 to 17 years, Pfizer COVID-19 vaccine is the only vaccine registered for use as a booster.

** Novavax can only be used as a booster if no other COVID-19 vaccine is suitable.

Information current as at 29 April 2022. Detailed information on ATAGI clinical guidelines for administration of COVID-19 vaccines is available at: www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance/clinical-recommendations